title: Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up.
abstract: Amegakaryocytic thrombocytopenia (AMT) is a rare cause of acquired thrombocytopenia. The pathogenesis and treatment of AMT is not clearly known. Here we demonstrate a 50-year-old man presented with the clinical manifestations of severe thrombocytopenia (7000 platelets/µl) with a marked decrease to absent of megakaryocytes in the bone marrow. The patient did not respond to intravenous immunoglobulin, cyclosporine or high dose prednisone. After the treatment with anti-CD20 antibody (Rituximab), the patient's clinical symptoms and platelet counts improved.
authors.affiliation: Imam Khomini Hospital Complex, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Mehrzad
authors.initials: M
authors.lastname: Mirzania
authors.affiliation: Arak University of Medical Sciences, Arak, Iran.
authors.forename: Sedigheh
authors.initials: S
authors.lastname: Khalili
authors.affiliation: Arak University of Medical Sciences, Arak, Iran.
authors.forename: Akbar
authors.initials: A
authors.lastname: Hasanpoor
authors.affiliation: Hematology-Oncology and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Ahmad Reza
authors.initials: AR
authors.lastname: Shamshiri
keywords: Amegakaryocytic thrombocytopenia; Anti-CD20 antibody; Platelet